Remoxipride

This MedLibrary.org supplementary page on Remoxipride is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Remoxipride
Systematic (IUPAC) name
3-Bromo-N-[ [(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide
Identifiers
CAS number 117591-79-4
ATC code N05AL04
PubChem 54477
DrugBank DB00409
Chemical data
Formula  ?
Mol. mass 371.27 g/mol
Pharmacokinetic data
Bioavailability C16H23BrN2O3
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.

Clinical trials

Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.

External links

Wikipedia content modification information:

  • This page was last modified on 31 July 2008, at 21:18.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Remoxipride".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.